Fueling the Circular Carbon Economy
Interview with Florian Hildebrand, Greenlyte Carbon Technologies
Innovation
Silicone Recycling without Loss of Quality
Interview with Klara Yoon, Tina Rose and Stephan Enthaler, New Dawn
Advanced Oxidation Treatment for Wastewater
Interview with Fajer Mushtaq and Silvan Staufert, Oxyle
Axplora Aims to Make Pharmaceutical Supply Chains More Stable
Interview with Sylke Hassel, previous CEO of PharmaZell and current CEO of Axplora following the merger with Novasep.
Expert Statement: Girish Malhotra, EPCOT International
Executives and industry experts share their views on drivers as well as barriers for the use of flow chemistry in pharmaceutical manufacturing and the prospect for this technology in their industry sector.
Chemistry and the „Next Normal”
Numerous crises such as climate change, energy shortages, raw material shortages, war in Ukraine and the consequences of the pandemic are putting value chains worldwide to the test.
Unlocking Forward-looking Data Analytics Synergies in the Materials Sector
Interview with Lisa Z. Mobech and Bjol R. Frenkenberger, MIR Insight
Bioforsense — From Waste to Value
CH-Bioforce, based in Raisio, Finland, strives for a cleaner world.
Halving Chemical Manufacturing Costs
Traditional batch chemistry is too inefficient for a sustainable future. Switching batch processing to continuous processing is inevitable if the world is to reach net zero.
Sustainable Industrial Wastewater Treatment
For decades, Ferrate(VI) has been known as the strongest oxidant in the world for the treatment of (industrial) wastewater.
Bachem Innovates its Manufacturing Capabilities
Interest in oligonucleotide therapeutics has grown, as has the market demand, since their emergence as a new drug modality two decades ago.
Expert Statement: Jean-Baptiste Guillermin, Axplora
Executives and industry experts share their views on drivers as well as barriers for the use of flow chemistry in pharmaceutical manufacturing and the prospect for this technology in their industry sector.
Expert Statement: Stephen D Drake, Kaneka Americas Holdings
Executives and industry experts share their views on drivers as well as barriers for the use of flow chemistry in pharmaceutical manufacturing and the prospect for this technology in their industry sector.
Expert Statement: Christophe Girard, Siegfried
Executives and industry experts share their views on drivers as well as barriers for the use of flow chemistry in pharmaceutical manufacturing and the prospect for this technology in their industry sector.
Expert Statement: Baburaj Krishnan, Aurigene Pharmaceutical Services
Executives and industry experts share their views on drivers as well as barriers for the use of flow chemistry in pharmaceutical manufacturing and the prospect for this technology in their industry sector.
Expert Statement: Mark Muldowney, Sterling Pharma Solutions
Executives and industry experts share their views on drivers as well as barriers for the use of flow chemistry in pharmaceutical manufacturing and the prospect for this technology in their industry sector.
Expert Statement: Ulrich Mayerhoeffer, Arxada
Executives and industry experts share their views on drivers as well as barriers for the use of flow chemistry in pharmaceutical manufacturing and the prospect for this technology in their industry sector.
Expert Statement: Srividya Ramakrishnan, Dr. Reddy’s Laboratories
Executives and industry experts share their views on drivers as well as barriers for the use of flow chemistry in pharmaceutical manufacturing and the prospect for this technology in their industry sector.
Expert Statement: Shawn Walker, Veranova
Executives and industry experts share their views on drivers as well as barriers for the use of flow chemistry in pharmaceutical manufacturing and the prospect for this technology in their industry sector.
Expert Statement: Kai Rossen, Euroapi
Executives and industry experts share their views on drivers as well as barriers for the use of flow chemistry in pharmaceutical manufacturing and the prospect for this technology in their industry sector.
New Covid Shots Score Points against Omicron
Sanofi and GSK are touting their latecomer protein-based Covid-19 vaccine as a potential game changer in the fight against the Omicron variant.
AI Makes Drug Discovery Faster
Interview with Joachim Haupt and Florian Kaiser, PharmAI
Nanoparticle Engineering
The value in applying AI in Pharma is in making new and better drugs available faster than would be possible otherwise. By augmenting sparse-data AI with expert knowledge and applying it to the latest nanoparticle engineering techniques, opportunities are created to eliminate the risk associated with new techniques and give therapeutics a second chance to reach the patients who need them.
Enabling the Best Possible Drug
Interview with Oliver Reimann and Andreas Regnery, Belyntic
Transforming the Scale-Up of Biobased Molecules
Interview with Jere Koskinen and Ali Harlin, Mega Cellulose.
Redesigning Tomorrow’s Plastics Today
B4Plastics is a Belgium-based biotechnology start-up and a polymer architecture company looking to catalyze the introduction of novel biomaterials and growing them from niche to bulk applications.
Artificial Intelligence for New Drug Design
Digital tools are a key to shortening the development of active pharmaceutical ingredients and thus market-ready drugs and therapies.
Rethinking the Base Material Side
Plafco Fibertech, founded in 2017, was created as a spin-off from an EU-research project coordinated by Jukka Valkama, a professor at the Cooperative State University of Baden Wurttemberg in Karlsruhe, Germany.
Paving the Way for Sustainable Infection Control
LipoCoat is a biotech company specialized in ‘bio-inspired’ coatings that improve the safety, comfort, and performance of medical devices with a focus on health and nutrition.
Vaccine Filling at the Highest Level
Recent studies show that contract manufacturers for the pharmaceutical industry, so-called CDMOs (contract development and manufacturing organizations), have so far been little involved in the production of vaccines. This is changing with the outbreak of the Covid-19 pandemic.
